Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222423 · ClinicalTrials.gov registry record
A Study of the Epidemiology and Hospital Management of Patients With PROS in France
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 3,605
- Enrollment target
NCT07222423 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 3,605 participants.
The verdict
NCT07222423 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 3,605 participants
- Enrollment target
Study Summary
The purpose of this study was to estimate the incidence and prevalence of a group of genetic disorders known as PIK3CA-Related Overgrowth Spectrum (PROS) in France. Additionally, the study aimed to characterize patients, disease management, and costs associated with PROS. This study used data from the French National Hospitals Database, Programme de Médicalisation des Systèmes d'Information (PMSI). The study period was from January 2015 to December 2022.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,605 participants |
| Start Date | 2024-01-15 |
| Est. Completion | 2024-10-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222423
The ClinicalTrials.gov registry entry for NCT07222423 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,605 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07222423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07222423 about?
NCT07222423 is a clinical study titled "A Study of the Epidemiology and Hospital Management of Patients With PROS in France". The purpose of this study was to estimate the incidence and prevalence of a group of genetic disorders known as PIK3CA-Related Overgrowth Spectrum (PROS) in France. Additionally, the study aimed to characterize patients, disease management, and costs associated with PROS. This study used data from t...
What is the current status of trial NCT07222423?
This trial is currently completed. The enrollment target is 3,605 participants. The study started on 2024-01-15. Estimated completion is 2024-10-08.
Who is sponsoring clinical trial NCT07222423?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.